MPO and Parkinson disease: The confluence of these several markers associated with the glymphatic system (GFAP, AQP4, LYVE1) and PD (MPO, HOCl-modified epitopes, carbsyn, ntSyn14) argue that MPO oxidants may be an important contributor to the impairment of the glymphatic system in PD.